CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
LEO43204 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02575950
NCT02575950Phase 2Completed

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 Applied in a Split-face (Left/Right) Topical Design in Adults With Moderate to Severe Acne

LEO Pharma·interventional·Posted Oct 15, 2015·Updated Mar 6, 2025

In Brief

A Phase 2 clinical trial evaluating LEO43204 and Placebo for Acne Vulgaris. Completed, enrolled 59 participants across 1 site.

Detailed Summary

An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 15, 2015
Enrollment StartJun 1, 2016
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.7 years ago

Interventions

LEO43204drug

Placebodrug